
ASX Announcement and Media Release

27 August 2004

SciGen Limited

Strong revenue growth and improved net result for FY2004.

The Directors of SciGen Limited ("SciGen" or the "Company") today released the Company's full year financial result for FY2004.

Financial Highlights:

- Net loss of S\$4.31M; an improvement of 12% over previous year.
- Revenue increase by 79% from prior year to S\$6.48M
- Major operating expenses well controlled. Additional expenditure in sales and marketing infrastructure and purchases related to increasing sales
- Cash receipts from customers up 173% from prior year to S\$5.4M
- Net cashflow from operating activities improved by S\$2.37M or 34% over the prior year
- Cash at bank at the end of the period S\$9.56M

Operational Highlights:

- Launch of recombinant human insulin (SciLin™) in Vietnam
- Sales of recombinant human insulin (SciLin™) commenced in Pakistan
- Considerable growth in SciTropin™ (recombinant human growth hormone) sales in Australia and Korea
- Registration (post balance date) of SciLin™ in India
- Registration of SciTropin™ in India with sales expected to commence during FY2005
- Sci-B-Vac™ (3rd generation hepatitis B vaccine) registered in Singapore
- Negotiation of commercialization agreement for SciLin™ in China
- Favourable renegotiation of licence agreement for Sci-B-Vac providing extended licence term; extension of supply rights (as distinct from marketing rights) from Asia Pacific region only to Worldwide rights; acquisition of rights for any hepatitis B therapeutic vaccine developed and Asia Pacific rights for combination vaccine.
- Announcement of discussions regarding potential strategic investment in the company.

Mark Compton- Managing Director of SciGen said significant revenue growth and its likely continuation confirmed the viability of the SciGen business model and the company's direction towards profitability.

"We are very pleased and excited by the fantastic year of growth and achievement. The company's revenue and cash receipts from sales continues to climb and we have achieved some very important operational milestones which will assist in continuing to build a strong commercial platform for the future."

“SciGen’s expertise in regulatory affairs, sales and marketing has achieved new registered products and higher sales and with human insulin now registered in India and in progress in China, two significant markets open up for the future,” Mr Compton said.

”With SciGen’s partnership with Shreya Biotechnology due to deliver a new US\$ 20M facility in India in the second half of FY05, we will have a competitive position in the very large Indian market and other locations,” Mr Compton added.

The renegotiation of the license agreement for Sci-B-Vac provides for another strong opportunity for the company. In particular securing worldwide supply rights for the hepatitis B vaccine and the rights to any therapeutic hepatitis B vaccine developed. As previously advised, the change in the manufacturing site for the vaccine will mean an interruption in supply to SciGen for a period of about 6 months. However, the expanded rights, license term and flexibility that comes with the revised agreement will be of significant benefit to the company going forward.

The company is working with its partners in India for the major launch of human insulin (SciLin™) in India in October this year.

SciGen will also be a major participant in a critical Asia-Pacific Regional Symposium on hepatitis B prevention and treatment in India to be held in December. This will provide an important platform to further showcase Sci-B-Vac prior to its expected registration in 2005.

Registration applications continue to be made and pursued for other products in the region. The most recent major submission was for SciLin™ in China. The company has previously announced a commercialisation agreement for insulin in China. The registration application will now move through due process with the Chinese authorities.

The company has previously advised the market that it is in discussions with a potential strategic investor into SciGen. The due diligence exercise is complete, and discussions are progressing positively on this potential investment. The market will be advised of further developments as they occur.

About SciGen

SciGen Ltd is a biopharmaceutical company essentially involved in commercialising later stage research. It co-develops and markets genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen’s portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which can allow for faster entry into the market, as biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in gaining regulatory approval and bringing products to market

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with offices also in Australia, USA, Korea, Vietnam, Hong Kong and Philippines and partners in India, China, Indonesia, Israel, Poland and the Netherlands.

=====ENDS=====

Media enquiries: Mark Compton, Managing Director & CEO
Telephone: +61 2 9234 1700; Web: www.scigen.com.au